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Bisphosphonates are well established in the management of cancer-induced bone disease. Recent studies have indicated that
these compounds have direct inhibitory effects on cultured human breast cancer cells. Nitrogen-containing bisphosphonates
including zoledronic acid have been shown to induce apoptosis associated with PARP cleavage and DNA fragmentation. The
aim of this study was to identify the signalling pathways involved. Forced expression of the anti-apoptotic protein bcl-2
attenuated bisphosphonate-induced loss of cell viability and induction of DNA fragmentation in MDA-MB-231 cells.
Zoledronic acid-mediated apoptosis was associated with a time and dose-related release of mitochondrial cytochrome c into
the cytosol in two cell lines. Rescue of cells by preincubation with a caspase-3 selective inhibitor and demonstration of pro-
caspase-3 cleavage products by immunoblotting suggests that at least one of the caspases activated in response to zoledronic
acid treatment is caspase-3. In both MDA-MB-231 and MCF-7 breast cancer cells, zoledronic acid impaired membrane
localisation of Ras indicating reduced prenylation of this protein. These observations demonstrate that zoledronic acid-
mediated apoptosis is associated with cytochrome c release and consequent caspase activation. This process may be initiated
by inhibition of the enzymes in the mevalonate pathway leading to impaired prenylation of key intracellular proteins including
Ras.
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Breast cancer commonly metastasises to bone: over 80% of women
with advanced breast cancer develop bone metastases which ulti-
mately account signiﬁcantly for morbidity and mortality.
Bisphosphonates (BPs) are potent inhibitors of bone resorption
and are effective in the treatment of many metabolic bone diseases.
In animal models of metastatic disease, BPs have been shown to
slow the development of bone metastases and to reduce tumour
burden in bone (Wingen et al, 1986; Yoneda et al, 2000). In
patients with advanced breast cancer and bone metastases, BPs
reduce the incidence of hypercalcaemia and skeletal morbidity
(Ryzen et al, 1985). In addition, a recently reported clinical trial
of patients with breast cancer has suggested that the BP clodronate
given in the adjuvant setting can reduce the incidence of skeletal
metastases with a consequent improvement in survival (Diel et
al, 1998). Such observations could indicate that BPs have direct
inhibitory effects on breast cancer cells. This suggestion is
supported by the demonstration that BPs inhibit breast cancer cell
adhesion to bone in vitro (van der Pluijm et al, 1996; Boissier et al,
1997).
We have recently demonstrated that two amino bisphosphonates
(N-BPs), pamidronate and zoledronic acid (ZOL), directly inhibit
growth and viability of cultured human breast cancer cells. These
effects are accompanied by morphological changes, induction of
DNA fragmentation, decreased bcl-2/bax ratio and PARP cleavage
indicative of caspase activation (Senaratne et al, 2000). These ﬁnd-
ings have been conﬁrmed by reports from two other groups that
provide evidence for caspase activation in N-BP-induced apoptosis
in breast cancer cells (Fromigue et al, 2000; Hiraga et al, 2001).
Initiation of the caspase cascade in response to many apoptotic
stimuli is a consequence of cytochrome c release from mitochon-
dria into the cytosol (Li et al, 1997; Zou et al, 1997). It has been
suggested that bcl-2 prevents the release of cytochrome c, thereby
inhibiting the activation of caspases (Marzo et al, 1998). One of
the aims of the present study was to clarify the involvement of
bcl-2 and cytochrome c in caspase activation induced by the N-
BP, ZOL in breast cancer cells. In this study we show for the ﬁrst
time that treatment of breast cancer cells with ZOL is associated
with release of mitochondrial cytochrome c into the cytosol consis-
tent with a decrease in the action of bcl-2. To further support a
relationship between bcl-2 and N-BP mediated apoptosis, we
now report that forced expression of bcl-2 abrogates ZOL-induced
DNA fragmentation which is a consequence of caspase activation
in breast cancer cells.
In order to identify further the mechanisms initiating this
caspase activation leading to N-BP-induced apoptosis in breast
cancer cells, we evaluated the possible role of impaired protein
prenylation. Recent pharmacological studies suggest that N-BPs
such as pamidronate, alendronate and risedronate act on the
enzymes in the mevalonate pathway leading to decreased genera-
tion of isoprenoid intermediates required for post-translational
prenylation of key cellular proteins. This is the suggested mechan-
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ma cells (Luckman et al, 1998; Shipman et al, 1998). However, the
identity of the proteins that are ineffectively prenylated following
N-BP treatment of breast cancer cells is presently unknown. Ras
proteins play pivotal roles in the control of normal and trans-
formed cell growth. For functional activity, Ras requires
membrane localisation and this is mediated by post-translational
modiﬁcation by the addition of a 15-carbon farnesyl isoprenoid.
By inhibiting farnesyl pyrophosphate (FPP) generation, N-BPs
might thus impair normal farnesylation of Ras. In this study we
present support for this potential mechanism and report for the
ﬁrst time that treatment with ZOL leads to impaired membrane
localisation of Ras protein in breast cancer cells that express both
wild-type and mutant ras.
METHODS
Cell lines
The breast cancer cell lines MDA-MB-231 (provided by Professor
RC Coombes, Imperial College, UK), and MCF-7 (Danish Cancer
Society, Copenhagen, Denmark), were maintained in Dulbecco’s
Modiﬁed Eagle Medium (DMEM) supplemented with
100 U ml
71 streptomycin and 5% foetal calf serum (FCS) at a
constant temperature of 37
oC with a humidiﬁed atmosphere of
5% CO2. Cells were routinely tested for mycoplasma contamina-
tion. Caspase-3 expressing MCF-7 cells, a kind gift from
Professor Alan Porter (The National University of Singapore,
Singapore), were maintained as above together with 200 mgm l
71
G418 sulphate (Geneticia, Life Technologies, Paisley, UK).
Reagents
Disodium salt of zoledronic acid ((1-hydroxy-2-imidazol-1-yl-phos-
phonoethyl) phosphonic acid) was obtained from Novartis
Pharmaceuticals Limited (Basle, Switzerland). Cell permeable
caspase-3 inhibitor 1 (Ac-Ala-Ala-Val-Ala-Leu-Leu-Pro-Ala-Val-
Leu-Leu-Ala-Leu-Leu-Ala-pro-Asp-Glu-Val-Asp-CHO) and tumour
necrosis factor alpha (TNF-a) were obtained from Calbiochem, CN
Biosciences (Nottingham, UK). Farnesol (3,7,11-Trimethyl-2-6,10-
dodecatrien-1-ol, mixed isomers), and trans, trans-geranylgeraniol
(all trans-3,7,11,15-tetramethyl-2,6,10,14-hexadecatetraenyl pyro-
phosphate) were obtained from Sigma-Aldrich Company Ltd
(Poole, Dorset, UK). The pUSEamp(+) plasmid containing wild-type
mouse bcl-2 under the control of the cytomegalovirus promoter was
obtained from Upstate Biotechnology (Lake Placid, NY, USA). A
control vector without the insert was obtained from the same source.
Measurement of cell viability
Cell viability was determined by 3-(4,5-dimethylthiazol-2-yl)-5-(3-
carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium (MTS)
dye reduction assay measuring mitochondrial respiratory function
(Cory et al, 1991). Breast cancer cells (2610
3 per well) were plated
into 96-well plates and treated with reagents or vehicle. At the end
of the treatment period, MTS dye (2 mg per 20 ml per well) was
added to the cell culture medium for 2 h. Absorbance was deter-
mined in a Titertek plate reader at 492 nm.
Immunoblotting
Breast cancer cells were harvested by scraping. Whole cell lysates
were prepared by washing the cells in ice cold phosphate buffered
saline (PBS) and resuspending in 100 ml of lysis buffer (20 mM
Tris, 40 mM sodium phosphate, 50 mM sodium ﬂuoride, 5 mM
magnesium chloride, 10 mM ethylene glycol-bis(b-aminoethyl
ether) N,N,N',N'-tetraacetic acid (EGTA), 0.5% sodium deoxycho-
late, 1% Triton X-100, 0.1% SDS, 40 mg ml
71 leupeptin,
100 mg ml
71 aprotinin, 20 mg ml
71 PMSF in Dimethyl sulphox-
ide (DMSO) and 50 mM sodium orthovanadate) for 30 min on ice.
Equivalent protein extracts (28 mg) from each sample were electro-
phoresed on 16% SDS-polyacralamide gels and proteins were
immobilised by transfer onto nitrocellulose membranes.
Membranes were immunoprobed with 5 mlm l
71 equivalent of
rabbit polyclonal antibodies against b actin (Sigma-Aldrich
Company LTD, UK) and caspase-3 (Santa Cruz, Heidelberg,
Germany) followed by a horseradish peroxidase-conjugated
secondary antibody to rabbit immunoglobulins (Amersham Inter-
national, UK). Speciﬁc bands were visualised by enhanced
chemiluminescence (ECL, Amersham International, UK).
To identify changes in membrane localisation of Ras, breast
cancer cells were treated with N-BPs or vehicle for 3 days and
harvested by scraping. Cells were disrupted by homogenisation
followed by ﬁve passes through a 25 gauge needle. Cytosolic and
membrane fractions were separated by centrifugation at
43000 r.p.m. for 25 min as previously described (Mumby et al,
1990). After solubilising in 0.01% SDS, the soluble fractions were
concentrated using Micron 10 microconcentrators (Vivascience,
Sartorius group, Goettingen, Germany). Equivalent protein extracts
(10 mg) of cytosol and membrane fraction from each sample were
electrophoresed on 12% SDS–PAGE mini gels. A mouse monoclo-
nal primary antibody generated against Ha-Ras protein p21, which
recognises wild-type and mutant Ras forms (Transduction Labora-
tories, CA, USA) was used to immunoprobe membranes. Proteins
were detected using a horseradish peroxidase-conjugated secondary
antibody to mouse immunoglobulins (Amersham International,
UK). Bands were visualised as described above. An equivalent
amount of total protein was loaded on to a separate mini gel
consisting only of SDS–PAGE stacking gel. After electrophoresing
for 30 min, depending on the contrast of the bands, gels were
either scanned fresh or bands were scanned after drying the gel
using a gel dryer.
To identify release of cytochrome c to the cytosol from the
mitochondria, breast cancer cells were treated with ZOL or vehicle
for 3 days and harvested on speciﬁed days by scraping. After wash-
ing the cells in ice cold PBS, they were resuspended in 500 mlo f
mitochondrial buffer (250 mM mannitol, 5 mM potassium dihydro-
gen orthophosphate, 10 mM ethylenediaminetetraacetic acid
(EDTA), 5 mM 3-(N-Morpholino) propanesulphonic acid
(MOPS)). Cell cytosol fraction was separated from the mitochon-
drial fraction by centrifugation at 13000 r.p.m. for 15 min at
48C and, after resuspending in the same supernatant, centrifuged
again at 13000 r.p.m. for a further 15 min as previously described
(Slee et al, 2000 ). The soluble (cytosol) fractions were concen-
trated using Micron 10 microconcentrators. Aliquots of cytosol
fractions with equivalent protein content (15 mg) from each sample
were electrophoresed on 15% SDS–PAGE mini gels. Mouse mono-
clonal primary antibodies generated against cytochrome c (BD
PharMingen, Becton Dickinson, NJ, USA) or b actin was used to
immunoprobe membranes. Proteins were detected using a horse-
radish peroxidase-conjugated secondary antibody to mouse
immunoglobulins. Bands were visualised as described above.
DNA fragmentation assay
Breast cancer cells were incubated with [
3H-methyl]-thymidine
(0.1 mCi ml
71) for 9–16 h to label DNA and then washed before
exposure to the indicated treatment. Cells were lysed with lysis
buffer and fragmented double stranded DNA was separated from
chromosome-length, unfragmented DNA followed by trichloro-
acetic acid (TCA) precipitation (Duke and Cohen, 1992).
Stable transfections
MDA-MB-231 cells were transfected with pUSEamp(+) bcl-2 plas-
mid or a control plasmid without insert, using SuperFectTM
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the manufacturers’ instructions. Selection of transfected clones
was done using culture medium containing 2 mg ml
71 G418
sulphate. Expression of bcl-2 was assessed by Western blotting
on whole cell lysates of selected clones using an antibody recog-
nising murine bcl-2 (DAKO, High Wycombe, UK)
Statistics
All experiments were performed at least twice and results shown
are mean of replicate samples (n=4) from a single experiment.
Statistical analysis of the data was carried out using analysis of
variance with ANOVA: Schiffe test using Statview 4.0 software
package for the Apple Macintosh. Statistical signiﬁcance is indi-
cated as **P50.0001 compared to control unless otherwise stated.
RESULTS
Suppression of ZOL-induced apoptosis by bcl-2
To elucidate the role of bcl-2 and ZOL-induced apoptosis in breast
cancer cells, we determined whether forced expression of bcl-2 was
capable of abrogating ZOL-induced loss of cell viability and DNA
fragmentation. Transfection of MDA-MB-231 cells with the
pUSEamp (+) plasmid containing a wild-type mouse bcl-2 resulted
in generation of at least two clones which stably over-expressed
bcl-2. Clone 1, which had the highest expression, and a control
transfected clone (C1) (Figure 1A), were used in subsequent experi-
ments to assess the role of bcl-2 in ZOL-induced apoptosis. The
inhibitory effects of ZOL on MDA-MB-231 cell viability was
suppressed by bcl-2 as clone 1 was shown to be signiﬁcantly less
sensitive than cells transfected with control vector (Figure 1B) or
parental cells (data not shown). Following treatment with 100 mM
ZOL for 3 days, loss of cell viability was signiﬁcantly attenuated
in cells over-expressing bcl-2 compared to control-vector trans-
fected cells. Furthermore, in cells transfected with control-vector,
100 mM ZOL induced a ﬁve-fold increase in DNA fragmentation
after 3 days of treatment compared to vehicle treated cultures
(Figure 1C). However in cultures over-expressing bcl-2 this
increase was less than two-fold compared to respective control.
Cytochrome c release
The anti-apoptotic members of the bcl-2 family of proteins inhibit
mitochondrial cytochrome c release and caspase activation. To
examine this aspect of the apoptotic pathway, MDA-MB-231 cells
were treated for up to 3 days with 100 mM ZOL and MCF-7 cells
were treated with 10, 50 and 100 mM of ZOL for 3 days, and the
appearance of cytochrome c in cytosol fractions was determined
by Western blot analysis. Figure 2A and C demonstrates that there
is an induction of cytochrome c release into the cytosol with
increasing time and concentration respectively of treatment with
ZOL. To our knowledge, this is the ﬁrst demonstration that mito-
chondrial cytochrome c release has been shown in association with
N-BP mediated apoptosis in any cell line.
ZOL treatment induces activation of caspase 3
On activation pro-caspase-3 (34 kD) is cleaved into two fragments
of 20 and 11 kD. To investigate the relationship of ZOL induced
cytochrome c release on effects on caspase-3 activation, MDA-
MB-231 cells were incubated for 3 days with ZOL (100 mM), cell
lysates were prepared and immunoblotting was carried out with
an antibody recognising pro-caspase-3 and its cleavage products.
Cleavage consistent with caspase-3 activation was observed in
ZOL treated cells, but only the 34 kD full-length pro-caspase-3
species was detected in control (vehicle treated) cultures (Figure
3A). Both pro-caspase-3 and its cleaved products were absent from
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Figure 1 (A) Immunoblotting of bcl-2 protein in whole cell extracts of
MDA-MB-231 clone-1 transfected with pUSEamp (+) plasmid containing
wild-type mouse bcl-2 and a clone transfected with control vector. Levels
of bcl-2 expression in transfected and control clones were compared rela-
tive to b actin protein. (B) Overexpression of bcl-2 suppresses ZOL effects
on breast cancer cells. Both control vector and bcl-2 overexpressing MDA-
MB-231 cells (clone 1) were incubated with 0, 50 and 100 mM ZOL for 3
days and cell viability was quantitated by MTS dye reduction assay. Clone 1
was shown to be signiﬁcantly less sensitive to ZOL induced reduction in cell
viability than cells transfected with control vector. Results are shown as
mean+s.d. Signiﬁcance was **P50.0001 compared to bcl-2-transfected
cells treated with 100 mM ZOL. (C) The induction of DNA fragmentation
by ZOL on MDA-MB-231 cells was signiﬁcantly inhibited in MDA-MB-231
clone 1, overexpressing bcl-2. Both control vector and clone 1 cells were
treated with 100 mM of ZOL for 3 days. Results are shown as mean+s.d..
ZOL treatment signiﬁcantly increased DNA fragmentation in control clone.
**P50.0001 (In bcl-2 transfected cells 100 mM of ZOL did not signiﬁcantly
increase DNA fragmentation. P=0.053).
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with TNF-a 12 ng ml
71 for 24 h (Figure 3A). MCF-7 cells do
not express caspase-3, but are still induced to undergo apoptosis
by a number of agents (Kurokawa et al, 1999) suggesting that cell
death could be associated with activation of another, as yet uniden-
tiﬁed caspase in these cells. To determine whether N-BPs can
modulate caspase-3 in these cells, we assessed effects of ZOL on
a transfected clone of MCF-7 cells stably expressing caspase-3.
These cells also underwent apoptosis with ZOL treatment as
assessed by loss of cell viability (data not shown) and cleavage of
pro-caspase-3 consistent with activation was observed after treat-
ment with ZOL for 3 days (Figure 3B).
To further conﬁrm the role of caspase-3 activation in ZOL-
mediated apoptosis, MDA-MB-231 cells were preincubated with a
caspase-3-selective inhibitor (0.5 mM) 3 h prior to addition of
ZOL (35 mM). After 24 h incubation, medium was removed and
replenished with fresh medium containing only the caspase-3 inhi-
bitor or DMSO vehicle. Results showed that the caspase-3-selective
inhibitor provided full protection against cell death induced by this
N-BP (Figure 3C), thus implicating activation of caspase-3 in its
mechanism of action.
Effects on membrane localisation of Ras
The initiating signal for N-BP mediated apoptosis in breast cancer
cells is presently unknown. However, it has been suggested
previously that N-BP-induced apoptosis in other cell types may
be associated with impaired prenylation of key cellular proteins.
Prenylation of Ras is required for its normal membrane localisation
and function (Rowinsky et al, 1999).
In order to determine if ZOL treatment affects Ras membrane
localisation, MDA-MB-231 cells, which have mutated K-ras
(Gilhooly and Rose, 1999), were incubated for 3 days with
100 mM ZOL and Ras protein levels in cytosol and membrane frac-
tions were determined by immunoblotting. Figure 4A demonstrates
that in control cultures Ras is predominantly associated with the
cell membrane fraction. However, in cultures treated with ZOL
for 3 days, Ras is predominantly found in the cytosol fraction
and the amount of Ras protein associated with the cell membrane
is greatly reduced. These results lend further support to the sugges-
tion that treatment of MDA-MB-231 cells with ZOL inhibits
generation of FPP leading to decreased prenylation of Ras. Similar
failure of Ras membrane localisation was seen with MCF-7 cells
(wild-type ras) treated with ZOL (Figure 4B) while co-treatment
with mixed isomers of farnesol (FOH) attenuated this effect.
Farnesol (mixed isomers) provides protection against
ZOL-induced loss of cell viability
In order to assess the efﬁcacy of various isoprenoids to attenuate
ZOL-mediated apoptosis, we determined effects of co-treatment
with farnesol (FOH mixed isomers) and all trans geranylgeraniol
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Figure 2 (A) MDA-MB-231 cells were incubated in the presence of 100 mM ZOL and cell extracts were prepared on speciﬁed days. Extracts were twice
centrifuged at 13000 r.p.m. for 15 min and the post-mitochondrial supernatant (cytosol) was concentrated as described in Materials and Methods. Cyto-
chrome c levels in samples having equivalent protein contents (15 mg) were determined by Western analysis. Lane order: 1, control cultures day 3; 2, ZOL
treated, day 1; 3, ZOL treated, day 2; and 4, ZOL treated, day 3. (B) Corresponding densitometric analysis of cytochrome c levels in cytosol for each day of
treatment. (C) MCF-7 cells were incubated in the presence of 10, 50 and 100 mM ZOL and cell extracts were prepared after 3 days of above treatments.
Cytosol fractions were prepared as described above and the cytochrome c levels in samples having equivalent protein contents (20 mg) were determined
using Western analysis. Lane order: 1, control cultures; 2, 10 mM ZOL; 3, 50 mM ZOL; and 4, 100 mM ZOL. (D) Corresponding densitometric analysis of
cytochrome c levels in cytosol for each treatment.
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were treated with 40 mM of each isoprenoid for 3 h prior to addi-
tion of ZOL. After 24 h co-treatment, media were removed and
replenished with fresh media containing isoprenoid or ethanol
vehicle only for a further 2 days. At the end of the treatment
period, cell viability was assessed by MTS assay. Co-treatment with
FOH (mixed isomers) protected against ZOL-induced apoptosis,
restoring viability to approximately 90% of control cultures. Co-
treatment with GGOH provided partial protection, since viability
of cultures co-treated with ZOL+GGOH was approximately 70%
of respective controls (Figure 5A,B). This study suggests that
impaired protein farnesylation may play a more important role
in N-BP mediated apoptosis in breast cancer cells than failure of
protein geranylgeranylation.
DISCUSSION
There is increasing evidence that BPs may have direct inhibitory
effects on breast cancer cells. These may be related to decreased cell
adhesion since pretreatment of MDA-MB-231 breast cancer cells
with BPs (ibandronate, olpandronate, pamidronate and alendro-
nate) prevents attachment and spreading of cells onto bone slices
(van der Pluijim et al, 1996; Boissier et al, 1997). Animal studies
have demonstrated that pretreatment of nude mice with BPs before
inoculation of tumour cells reduces the development of osteolytic
lesions (Sasaki et al, 1995). Furthermore, a recent study using an
in vitro model of cell invasion has suggested that BPs may inhibit
this early event in the formation of bone metastases (Boissier et al,
2000). We have shown that BPs directly induce apoptosis in breast
cancer cells and this observation has recently been conﬁrmed by
other studies (Fromigue et al, 2000; Hiraga et al, 2001; Jagdev et
al, 2001). Our present analysis of the apoptotic pathways affected
by ZOL provides insight into the mechanism by which N-BPs
induce cell death in breast cancer cells. The bcl-2 family of pro-
and anti-apoptotic proteins plays an important role in apoptosis
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Figure 3 (A) Identiﬁcation of caspase-3 activity in breast cancer cells.
MDA-MB-231 cells were incubated in the presence of 100 mM ZOL for
3 days before cell extracts were prepared and Western blot analysis carried
out. Two prominent cleaved products of pro-caspase-3 (indicating caspase
activation) were seen at 20 and 11 kD. Lane order: 1, MDA-MB-231 cells
treated with vehicle alone; 2, MDA-MB-231 treated with taxotere 10 nM
for 2 days as a positive control; 3, MCF-7 treated with TNF-a 20 ng ml
71
for 2 days, as a negative control; 4, MDA-MB-231 treated with pamidronate
100 mM and 5, MDA-MB-231 treated with ZOL 100 mM.( B) Identiﬁcation
of caspase-3 activation by ZOL in MCF-7 cells with forced expression of
caspase-3. Both control vector and caspase-3 expressing MCF-7 cells were
incubated with 100 mM ZOL for 3 days before cell extracts were prepared
and Western blot analysis carried out. Lane order: 1, Control vector MCF-7
treated with vehicle alone; 2, Control vector MCF-7 treated with ZOL; 3,
Caspase-3 expressing MCF-7 treated with vehicle alone and 4, caspase-3
expressing MCF-7 treated with ZOL. (C) Attenuation of ZOL effects by
a caspase-3-selective inhibitor. MDA-MB-231 cells were treated with the
caspase-3 inhibitor (0.5 mM) 3 h prior to addition of 35 mM of ZOL for
24 h. Medium was then replaced with medium containing either the cas-
pase-3 inhibitor or vehicle (DMSO) alone. On day 3 cell viability was quan-
titated using MTS dye reduction assay. Results are shown as mean+s.d.
Signiﬁcance levels were
a P50.0005 vs untreated cells,
b P50.0005 vs
ZOL treated cells.
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Figure 4 (A) Identiﬁcation of ZOL induced reduction in active Ras
(membrane bound) in MDA-MB-231 cells. MDA-MB-231 cells were trea-
ted with 100 mM ZOL for 3 days. Level of expression of Ras protein in
cytosol and membrane fractions was determined by Western analysis
and equivalence of loading was determined by total protein staining as de-
scribed in Materials and Methods. Lane order: 1, membrane fraction; 2, cy-
tosol fraction. (B) MCF-7 cells were treated with 40 mM of FOH (mixed
isomers) 3 h before addition of 50 mM ZOL for 24 h. Medium was then
replaced with fresh medium containing 40 mM FOH (mixed isomers) or ve-
hicle only for a further 2 days. Level of expression of Ras protein in cytosol
and membrane fractions following each treatment was determined by
Western analysis as described above. Equivalence of loading was deter-
mined by total protein staining as described in Materials and Methods. Lane
order: 1, membrane fraction; 2, cytosol fraction.
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suggested that bcl-2 prevents the release of cytochrome c into the
cytosol, thereby inhibiting the activation of caspases (Marzo et al,
1998). An aim of the present study was to clarify the involvement
of bcl-2 and cytochrome c release in ZOL mediated caspase activa-
tion in breast cancer cells. We have already shown that bcl-2
protein is down-regulated upon treatment of breast cancer cells
with N-BPs (Senaratne et al, 2000) and now report that forced
expression of bcl-2 in MDA-MB-231 breast cancer cells efﬁciently
inhibits ZOL-induced DNA fragmentation, which is a consequence
of caspase activation in breast cancer cells. These results are in
agreement with a study carried out on myeloma cells demonstrat-
ing that forced expression of bcl-2 is capable of abrogating BP
induced apoptosis (Aparicio et al, 1998). We now demonstrate
for the ﬁrst time that treatment of breast cancer cells with ZOL
is associated with release of mitochondrial cytochrome c into the
cytosol.
Support for the role of caspase activation in N-BP-induced
apoptosis in breast cancer cells is provided by demonstration of
PARP cleavage (Senaratne et al, 2000) as well as abrogation by z-
VAD-fmk (a broad-spectrum caspase inhibitor) of MCF-7 cell
growth inhibition induced by four BPs (zoledronic acid, ibandro-
nate, pamidronate and clodronate, Fromigue et al, 2000).
Activation of caspase-3-like proteases is thought to be an
irreversible step in the pathway leading to DNA fragmentation in
apoptotic cell death (Cohen, 1997). Hiraga et al (2001) have
demonstrated that a selective caspase-3 inhibitor is capable of
blocking ibandronate-induced DNA fragmentation in MDA-MB-
231 breast cancer cells and we have similarly found that caspase-
3 inhibition signiﬁcantly protects against ZOL-induced loss of
viability in these cells.
Furthermore, in the present study we have presented direct
evidence for activation of this cell death protease by ZOL in
MDA-MB-231 breast cancer cells by immunoblotting. We and
others (Fromigue et al, 2000; Senaratne et al, 2000; Jagdev et al,
2001) have demonstrated that N-BPs are capable of inducing loss
of cell viability and DNA fragmentation in MCF-7 cells which
are caspase-3 null (Kurokawa et al, 1999). However, our present
study illustrates that in MCF-7 cells stably transfected with
caspase-3, ZOL is capable of activating this cell-death protease.
We suggest that in parental MCF-7 cells, treatment with N-BPs
is associated with activation of another caspase, possibly caspase
7 (Puig et al, 2001).
How does treatment of breast cancer cells with N-BPs lead to
cytochrome c release and caspase activation? In order to address
this question we evaluated the possible role of impaired protein
prenylation. Recent pharmacological studies suggest that N-BPs
such as pamidronate, alendronate and risedronate act on the
cholesterol biosynthetic pathway (Luckman et al, 1998; Shipman
et al, 1998). N-BPs such as ZOL have recently been shown to inhi-
bit farnesyl pyrophosphate synthase (van Beek et al, 1999a;
Dunford et al, 2001) thus blocking the production of the pyropho-
sphate intermediates FPP and GGPP. These intermediates are
important for post-translational modiﬁcation of key regulatory
proteins. Prenylation of small G proteins such as Rac, Rho and
various members of the Rab family occurs through transfer of
either one or two 20 carbon geranylgeranyl isoprenoids from GGPP
to these proteins (reviewed in Rowinsky, 1999) by the action of
geranylgeranyl transferases (GGTases). Another key prenylated
protein is Ras, which undergoes farnesylation by the addition of
a 15-carbon farnesyl isoprenoid from FPP by the action of farnesyl
transferase (FTase). Failure of FPP and GGPP generation by inhibi-
tion of FPP synthase would thus be expected to lead to impaired
prenylation of these important regulatory proteins.
Ras proteins play pivotal roles in the control of normal and
transformed cell growth. While ras mutations are not as common
in breast cancer as in some other types of malignancy, the
increased activity of growth factor signalling pathways which are
mediated via Ras proteins makes targeting Ras action an attractive
option in breast cancer treatment. By preventing maturation into
its biologically active form, farnesyl transferase inhibitors (FTIs)
abolish the membrane localisation (Lerner et al, 1995) and function
of Ras (Nagase et al, 1996) and these agents are currently under
evaluation in clinical trials in patients with breast cancer (Johnston
and Kelland, 2001). We have determined if N-BPs can also prevent
Ras processing leading to its cytoplasmic accumulation. In MDA-
MB-231 and MCF-7 cells, treatment with ZOL for 3 days clearly
prevented membrane localisation of Ras as determined by immu-
noblotting. Therefore our results suggest for the ﬁrst time that
N-BPs inhibit Ras processing and membrane localisation in breast
cancer cells in a manner similar to FTIs.
To investigate the role of protein prenylation in N-BP mediated
apoptosis in breast cancer cells further, we determined if replace-
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Figure 5 (A) Effects of FOH (mixed isomers) on ZOL-induced inhibi-
tion of cell viability. MDA-MB-231 cells were treated with or without
40 mM of FOH (mixed isomers) 3 h before addition of 40 mM ZOL for
24 h. Medium was then replaced with fresh medium containing 40 mM
FOH (mixed isomers) or vehicle (ethanol) only for a further 3 days. Results
are shown as mean+s.d. Signiﬁcance
a P50.0001 vs vehicle treated cells
(control).
b P50.0001 vs ZOL alone treated cells. Control vs ZOL +
FOH was not signiﬁcant (P=0.86). (B) Effects of all trans-GGOH (40 mM)
on ZOL induced inhibition of cell viability. MDA-MB-231 cells were treated
with or without 40 mM all trans-GGOH for 3 h before exposing to 40 mM
of ZOL for 24 h. Medium was then replaced with fresh medium containing
40 mM all trans-GGOH alone or vehicle only. Results are shown as
mean+s.d. Signiﬁcance
a P50.0001 vs vehicle treated cells (control).
b
P50.0014 vs ZOL alone treated cells. Viability of cultures treated with
ZOL+GGOH was signiﬁcantly lower than control (P50.01).
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from ZOL-induced apoptosis. In most studies designed to investi-
gate this potential mechanism in osteoclasts and macrophages, the
ability of FOH and GGOH to prevent effects of N-BPs have been
utilised. These analogues of FPP and GGPP have been reported to
display greater membrane permeability and be converted to the
respective pyrophosphate forms intracellularly by a salvage pathway
(Crick et al, 1997). In osteoclasts, N-BP-induced apoptosis was
attenuated by addition of GGOH but not FOH (Fisher et al,
1999; van Beek et al, 1999b). However, in J774 macrophages
undergoing N-BP induced apoptosis, addition of either FOH or
GGOH (Benford et al, 1999) inhibited caspase-3 activation and
induction of apoptosis. Our present study in breast cancer cells
has shown that FOH (mixed isomers) both protects MDA-MB-
231 cells from ZOL-induced inhibition of cell viability and attenu-
ates ZOL-induced loss of Ras membrane localisation in MCF-7
cells. This suggests that Ras is one important prenylated protein
that is altered in activity by N-BP treatment of breast cancer cells.
We found that co-treatment with GGOH was less effective than
FOH in protecting MDA-MB-231 cells from ZOL-induced apopto-
sis. This is in contrast to a recent study by Jagdev et al (2001) who
reported that co-treatment with GGOH rescued MCF-7 cells from
ZOL induced apoptosis whereas FOH had little effect.
Taken together our present results demonstrate that ZOL
induces apoptosis in human breast cancer cells. This apoptosis is
associated with release of cytochrome c into the cytosol and subse-
quent activation of the caspase cascade. These effects are abrogated
by forced expression of bcl-2. Our results implicate a role for
protein prenylation and impaired Ras membrane localisation in
apoptosis. Further research is likely to provide valuable insights
into the role played by prenylated proteins in the initiation of these
apoptotic pathways. Currently BPs are used in the treatment of
patients who develop bone metastases from carcinoma of the
breast. The primary aim here is to reduce the skeletal morbidity
such as bone pain, fracture and hypercalcaemia (Hortobagyi et
al, 1996; Body et al, 1998). At present, the report by Diel et al
(1998) is the only one to demonstrate a survival advantage with
the use of clodronate in the adjuvant setting. With the advent of
the newer and more potent BPs such as ZOL, the potential to make
an impact on progression-free and overall survival may be
achieved. Knowledge of the various pathways involved may facili-
tate additional therapeutic interventions to maximise the effects
of BPs.
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